You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetaxalone
Accession NumberDB00660  (APRD00514)
TypeSmall Molecule
GroupsApproved
DescriptionMetaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin®) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.
Structure
Thumb
Synonyms
Metassalone
Metaxalon
Metaxalona
Metaxalonum
Skelaxin
External Identifiers
  • AHR 438
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxaloneTablet800 mg/1OralDispensing Solutions, Inc.2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralSTAT Rx USA LLC2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralBlenheim Pharmacal, Inc.2010-05-20Not applicableUs
MetaxaloneTablet800 mg/1Oralbryant ranch prepack2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralPd Rx Pharmaceuticals, Inc.2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralA S Medication Solutions2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralUnit Dose Services2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralCore Pharma, Llc2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-06Not applicableUs
MetaxaloneTablet800 mg/1OralPreferred Pharmaceuticals, Inc.2014-02-14Not applicableUs
MetaxaloneTablet800 mg/1OralPd Rx Pharmaceuticals, Inc.2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralDIRECT RX2014-01-01Not applicableUs
MetaxaloneTablet800 mg/1OralNorthwind Pharmaceuticals2014-04-01Not applicableUs
MetaxaloneTablet800 mg/1OralCarilion Materials Management2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralRebel Distributors Corp2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralSt. Marys Medical Park Pharmacy2011-01-30Not applicableUs
MetaxaloneTablet800 mg/1OralREMEDYREPACK INC.2012-03-29Not applicableUs
MetaxaloneTablet800 mg/1Oralbryant ranch prepack2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralSTAT Rx USA LLC2007-11-01Not applicableUs
MetaxaloneTablet800 mg/1OralH.J. Harkins Company, Inc.2007-11-01Not applicableUs
SkelaxinTablet800 mg/1OralPhysicians Total Care, Inc.2003-01-30Not applicableUs
SkelaxinTablet800 mg/1OralPfizer Laboratories Div Pfizer Inc2002-08-30Not applicableUs
SkelaxinTablet800 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
SkelaxinTablet800 mg/1OralRebel Distributors Corp1962-08-13Not applicableUs
SkelaxinTablet800 mg/1OralPreferred Pharmaceuticals, Inc2003-01-30Not applicableUs
SkelaxinTablet800 mg/1OralCardinal Health2002-08-30Not applicableUs
SkelaxinTablet800 mg/1OralBlenheim Pharmacal, Inc.2010-03-15Not applicableUs
SkelaxinTablet800 mg/1OralPd Rx Pharmaceuticals, Inc.2002-08-30Not applicableUs
SkelaxinTablet800 mg/1OralSTAT Rx USA LLC2002-08-30Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MetaxallTablet800 mg/1OralSircle Laboratories, Llc2015-09-25Not applicableUs
MetaxaloneTablet800 mg/1OralA S Medication Solutions2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralGemini Laboratories, LLC2015-12-30Not applicableUs
MetaxaloneTablet800 mg/1OralEon Labs, Inc.2010-03-31Not applicableUs
MetaxaloneTablet800 mg/1OralBlenheim Pharmacal, Inc.2013-09-11Not applicableUs
MetaxaloneTablet800 mg/1OralAmerican Health Packaging2013-12-18Not applicableUs
MetaxaloneTablet800 mg/1OralPreferred Pharmaceuticals, Inc.2015-01-06Not applicableUs
MetaxaloneTablet800 mg/1OralNorthwind Pharmaceuticals2014-02-12Not applicableUs
MetaxaloneTablet800 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralDIRECT RX2015-01-01Not applicableUs
MetaxaloneTablet800 mg/1OralAv Kare, Inc.2015-05-22Not applicableUs
MetaxaloneTablet800 mg/1OralRebel Distributors Corp.2010-03-31Not applicableUs
MetaxaloneTablet800 mg/1OralKeltman Pharmaceuticals Inc.2008-06-25Not applicableUs
MetaxaloneTablet800 mg/1OralA S Medication Solutions2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralAmneal Pharmaceuticals of New York, LLC2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralPreferred Pharmaceuticals Inc.2016-08-02Not applicableUs
MetaxaloneTablet800 mg/1OralProficient Rx LP2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralClinical Solutions Wholesale2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralAidarex Pharmaceuticals LLC2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralNorthwind Pharmaceuticals2016-01-27Not applicableUs
MetaxaloneTablet800 mg/1OralPhysicians Total Care, Inc.2010-04-07Not applicableUs
MetaxaloneTablet800 mg/1OralSolis Generic Pharmaceuticals Llc2016-10-21Not applicableUs
MetaxaloneTablet800 mg/1OralAmneal Pharmaceuticals, LLC2013-05-31Not applicableUs
MetaxaloneTablet800 mg/1OralBlue Point Laboratories2014-04-22Not applicableUs
MetaxaloneTablet800 mg/1OralAv Pak2015-03-13Not applicableUs
MetaxaloneTablet400 mg/1OralCore Pharma, Llc2015-03-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1NMA9J598Y
CAS number1665-48-1
WeightAverage: 221.2524
Monoisotopic: 221.105193351
Chemical FormulaC12H15NO3
InChI KeyIMWZZHHPURKASS-UHFFFAOYSA-N
InChI
InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)
IUPAC Name
5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one
SMILES
CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1
Pharmacology
IndicationFor the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.
Structured Indications
PharmacodynamicsMetaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.
Mechanism of actionThe mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.
Related Articles
AbsorptionThe absolute bioavailability of metaxalone from Skelaxin tablets is not known.
Volume of distribution
  • 800 L
Protein bindingNot Available
Metabolism

Probably hepatic.

Route of eliminationMetaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
Half life9.2 (+/- 4.8) hours
Clearance
  • 68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
  • 66 +/- 51 L/h [Subjects received 2×400 mg tablets under fasted conditions]
ToxicityLD50=775mg/kg (Rat, oral); LD50=1690 mg/kg (Mouse, oral). When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Metaxalone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Metaxalone.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Metaxalone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Metaxalone.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Metaxalone.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Metaxalone.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Metaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metaxalone.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metaxalone.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Metaxalone.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Metaxalone.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Metaxalone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Metaxalone.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Metaxalone.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Metaxalone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Metaxalone.Vet Approved
AzelastineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Metaxalone.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Metaxalone.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Metaxalone.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Metaxalone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Metaxalone.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Metaxalone.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Metaxalone.Approved, Investigational
BuprenorphineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Metaxalone.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Metaxalone.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Metaxalone.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Metaxalone.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metaxalone.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metaxalone.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Metaxalone.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Metaxalone.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Metaxalone.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metaxalone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Metaxalone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Metaxalone.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Metaxalone.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Metaxalone.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Metaxalone.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Metaxalone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Metaxalone.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Metaxalone.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Metaxalone.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metaxalone.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Metaxalone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Metaxalone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Metaxalone.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone.Approved
DesipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Metaxalone.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metaxalone.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metaxalone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metaxalone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Metaxalone.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Metaxalone.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metaxalone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metaxalone.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metaxalone.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metaxalone.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Metaxalone.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Metaxalone.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Metaxalone.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Metaxalone.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Metaxalone.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Metaxalone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Metaxalone.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Metaxalone.Approved
EthanolMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.Approved
EthotoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Metaxalone.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Metaxalone.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metaxalone.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Metaxalone.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Metaxalone.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Metaxalone.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Metaxalone.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Metaxalone.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Metaxalone.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Metaxalone.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Metaxalone.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Metaxalone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Metaxalone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Metaxalone.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Metaxalone.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Metaxalone.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Metaxalone is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Metaxalone.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Metaxalone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Metaxalone.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Metaxalone.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Metaxalone.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Metaxalone.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Metaxalone.Approved
HydrocodoneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metaxalone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Metaxalone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metaxalone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metaxalone.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metaxalone.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metaxalone.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Metaxalone.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Metaxalone.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Metaxalone.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metaxalone.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Metaxalone.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Metaxalone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Metaxalone.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Metaxalone.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Metaxalone.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Metaxalone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Metaxalone.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metaxalone.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Metaxalone.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Metaxalone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Metaxalone.Approved
MethotrimeprazineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Metaxalone.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Metaxalone.Approved
MetyrosineMetaxalone may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Investigational
MirtazapineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Metaxalone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metaxalone.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Metaxalone.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Metaxalone.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Metaxalone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metaxalone.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Metaxalone.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Metaxalone.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Metaxalone.Approved, Illicit
OrphenadrineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Metaxalone.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Metaxalone.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Metaxalone.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Metaxalone.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metaxalone.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.Approved
ParaldehydeMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Metaxalone.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
PerazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Metaxalone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Metaxalone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metaxalone.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metaxalone.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Metaxalone.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Metaxalone.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Metaxalone.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metaxalone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.Approved
PramipexoleMetaxalone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Metaxalone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Metaxalone.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Metaxalone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Metaxalone.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Metaxalone.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Metaxalone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Metaxalone.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Metaxalone.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Metaxalone.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.Approved
RacloprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Metaxalone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Metaxalone.Vet Approved
RopiniroleMetaxalone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone.Approved
RotigotineMetaxalone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Metaxalone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Metaxalone.Experimental
Sage 547The risk or severity of adverse effects can be increased when Metaxalone is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Metaxalone.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metaxalone.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metaxalone.Approved
SuvorexantMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Metaxalone.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Metaxalone.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Metaxalone.Investigational
ThalidomideMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Metaxalone.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Metaxalone.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metaxalone.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.Approved
TiagabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Metaxalone.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Metaxalone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metaxalone.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Metaxalone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Metaxalone.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Metaxalone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Metaxalone.Approved
Uc1010The risk or severity of adverse effects can be increased when Metaxalone is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Metaxalone.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metaxalone.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Metaxalone.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Metaxalone.Vet Approved
ZolpidemMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Metaxalone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Metaxalone.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Spiridon Spireas, “Bioavailable compositions of metaxalone and processes for producing the same.” U.S. Patent US20050276844, issued December 15, 2005.

US20050276844
General References
  1. See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. [PubMed:18711953 ]
  2. Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [PubMed:6999895 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (124 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9747
Caco-2 permeable+0.5076
P-glycoprotein substrateNon-substrate0.7072
P-glycoprotein inhibitor INon-inhibitor0.8309
P-glycoprotein inhibitor IINon-inhibitor0.906
Renal organic cation transporterNon-inhibitor0.8464
CYP450 2C9 substrateNon-substrate0.8154
CYP450 2D6 substrateNon-substrate0.7182
CYP450 3A4 substrateNon-substrate0.5649
CYP450 1A2 substrateInhibitor0.6863
CYP450 2C9 inhibitorNon-inhibitor0.7448
CYP450 2D6 inhibitorNon-inhibitor0.7733
CYP450 2C19 inhibitorNon-inhibitor0.6471
CYP450 3A4 inhibitorNon-inhibitor0.911
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.797
Ames testNon AMES toxic0.6074
CarcinogenicityNon-carcinogens0.9312
BiodegradationNot ready biodegradable0.9544
Rat acute toxicity2.4250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.913
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sandoz inc
  • King pharmaceuticals inc
  • Elan Corporation
Packagers
Dosage forms
FormRouteStrength
TabletOral400 mg/1
TabletOral800 mg/1
Prices
Unit descriptionCostUnit
Metaxalone 800 mg tablet3.88USD tablet
Skelaxin 800 mg tablet3.84USD tablet
Skelaxin 400 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6407128 No2001-12-032021-12-03Us
US7122566 No2006-02-062026-02-06Us
US7714006 No2001-12-032021-12-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point122 °CPhysProp
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.28 mg/mLALOGPS
logP1.63ALOGPS
logP2.37ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)13.14ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area47.56 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.32 m3·mol-1ChemAxon
Polarizability23.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Alkyl aryl ether
  • Oxazolidinone
  • Oxazolidine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 04, 2016 02:42